Theravalues Release: A Clinical Study Shows the Theracurmin®'s Safety and Potential Role in Improving Quality of Life (QOL) of Pancreatic Cancer Patients
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TOKYO--(BUSINESS WIRE)--Theravalues, Japan-based biotechnology innovator, announced today that a recent phase I clinical trial on the pancreatic cancer patients using Theracurmin®, an enhanced form of curcumin that allows for greater absorption, has no adverse effect for both of dose levels (200mg/day and 400mg/day) on cancer patients. The study also discovered that the Theracurmin® dosage helped improve a whole range of Quality of Life (QOL) scores of the patients.
Help employers find you! Check out all the jobs and post your resume.
TOKYO--(BUSINESS WIRE)--Theravalues, Japan-based biotechnology innovator, announced today that a recent phase I clinical trial on the pancreatic cancer patients using Theracurmin®, an enhanced form of curcumin that allows for greater absorption, has no adverse effect for both of dose levels (200mg/day and 400mg/day) on cancer patients. The study also discovered that the Theracurmin® dosage helped improve a whole range of Quality of Life (QOL) scores of the patients.
Help employers find you! Check out all the jobs and post your resume.